BRPI0906810A2 - anticorpo contra pcrv - Google Patents

anticorpo contra pcrv

Info

Publication number
BRPI0906810A2
BRPI0906810A2 BRPI0906810A BRPI0906810A BRPI0906810A2 BR PI0906810 A2 BRPI0906810 A2 BR PI0906810A2 BR PI0906810 A BRPI0906810 A BR PI0906810A BR PI0906810 A BRPI0906810 A BR PI0906810A BR PI0906810 A2 BRPI0906810 A2 BR PI0906810A2
Authority
BR
Brazil
Prior art keywords
pcrv
monoclonal antibody
present
pharmaceutical composition
pseudomonas aeruginosa
Prior art date
Application number
BRPI0906810A
Other languages
English (en)
Inventor
Sato Takafumi
Tsuji Toshinaga
Yamano Yoshinori
Numata Yoshito
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0906810A2 publication Critical patent/BRPI0906810A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"anticorpos monoclonais contra pcrv ou parte dos mesmos, sua composição farmacêutica, hibridoma e uso dos referidos anticorpos". a presente invenção refere-se a um meio eficaz para terapia de infecção, particularmente infecção com pseudomonas aeruginosa. refere-se a um anticorpo monoclonal contra pcrv, ou uma parte do mesmo, e uma composição farmacêutica contendo o mesmo como um ingrediente ativo. concretamente, o anticorpo monoclonal da presente invenção tem excelente atividade de inibição sobre citotoxicidade com relação a uma célula-alvo de pseudomonas aeruginosa. também, o anticorpo monoclonal da presente invenção tem alta afinidade com pcrv.
BRPI0906810A 2008-01-10 2009-01-08 anticorpo contra pcrv BRPI0906810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008003214 2008-01-10
PCT/JP2009/050118 WO2009088032A1 (ja) 2008-01-10 2009-01-08 ＰｃｒＶに対する抗体

Publications (1)

Publication Number Publication Date
BRPI0906810A2 true BRPI0906810A2 (pt) 2019-10-01

Family

ID=40853144

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906810A BRPI0906810A2 (pt) 2008-01-10 2009-01-08 anticorpo contra pcrv

Country Status (13)

Country Link
US (1) US8501179B2 (pt)
EP (2) EP2599792A1 (pt)
JP (1) JP4766716B2 (pt)
KR (1) KR101259239B1 (pt)
CN (1) CN102137870B (pt)
AU (1) AU2009203426C1 (pt)
BR (1) BRPI0906810A2 (pt)
CA (1) CA2711863C (pt)
EA (1) EA020544B1 (pt)
ES (1) ES2426093T3 (pt)
PL (1) PL2248826T3 (pt)
PT (1) PT2248826E (pt)
WO (1) WO2009088032A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2599792A1 (en) 2008-01-10 2013-06-05 Shionogi&Co., Ltd. Antibody directed against PcrV
CA2754900A1 (en) * 2009-03-11 2010-09-16 Shionogi & Co., Ltd. Humanized pcrv antibody having anti-pseudomonal activity
MX349886B (es) 2011-06-10 2017-08-17 Medimmune Llc Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
US10072098B2 (en) * 2012-03-02 2018-09-11 Ablynx N.V. Pseudomonas aeruginosa PCRV binding single variable domain antibodies
CN113966343A (zh) 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0729976A1 (en) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6309651B1 (en) 1998-11-25 2001-10-30 Mcw Research Foundation Method of and compositions for immunization with the pseudomonas V antigen
US20030228324A1 (en) * 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
EP1353688B1 (en) 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
EP2990053A1 (en) * 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
SG170804A1 (en) 2006-03-30 2011-05-30 Meiji Seika Kaisha Pseudomonas aeruginosa outer membrane protein pa0427
CN101002947B (zh) * 2007-01-16 2010-08-25 湖南农业大学 一种用于细菌病治疗的靶向药物及其制备方法
CN101878302A (zh) 2007-06-29 2010-11-03 明治制果株式会社 绿脓杆菌的外膜蛋白质pa4710
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2599792A1 (en) 2008-01-10 2013-06-05 Shionogi&Co., Ltd. Antibody directed against PcrV
CA2754900A1 (en) * 2009-03-11 2010-09-16 Shionogi & Co., Ltd. Humanized pcrv antibody having anti-pseudomonal activity

Also Published As

Publication number Publication date
WO2009088032A1 (ja) 2009-07-16
CN102137870B (zh) 2014-09-03
KR101259239B1 (ko) 2013-04-29
AU2009203426A1 (en) 2009-07-16
CA2711863C (en) 2014-06-10
PL2248826T3 (pl) 2013-11-29
PT2248826E (pt) 2013-09-06
ES2426093T3 (es) 2013-10-21
EP2248826A4 (en) 2011-03-02
AU2009203426C1 (en) 2012-05-31
EP2599792A1 (en) 2013-06-05
JP4766716B2 (ja) 2011-09-07
EA020544B1 (ru) 2014-12-30
EP2248826B1 (en) 2013-06-12
JPWO2009088032A1 (ja) 2011-05-26
KR20100103675A (ko) 2010-09-27
US8501179B2 (en) 2013-08-06
EA201070826A1 (ru) 2011-04-29
CN102137870A (zh) 2011-07-27
AU2009203426B2 (en) 2011-11-24
EP2248826A1 (en) 2010-11-10
CA2711863A1 (en) 2009-07-16
US20110150896A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
BRPI0906810A2 (pt) anticorpo contra pcrv
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BRPI0811262A2 (pt) Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
WO2013122932A4 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
EP2379060A4 (en) PHARMACEUTICAL FORMULATIONS WITH EXTENDED RELEASE
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
CL2009000555A1 (es) Compuestos derivados de tetramatos sustituidos espirociclicamente con 4'4'-dioxaespiro; procedimiento de preparacion; agente para combatir plagas y/o vegetaciones indeseadas que comprende dichos compuestos; su procedimiento de preparacion y uso; composiciones y su uso
CR10032A (es) Preparación sólida
BRPI0801858A2 (pt) uso de pelo menos um meio de cultura celular condicionado ou de seu extrato e composiÇço cosmÉtica ou dermatolàgica
CL2011002300A1 (es) Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
BRPI0920355B8 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
EP2826771A3 (en) Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
BR0312921A (pt) Composição compreendendo inibidor de reductase hmg-coa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]